Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik sold 36,979 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $37.30, for a total value of $1,379,316.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Karyopharm Therapeutics (NASDAQ:KPTI) traded down 0.19% on Wednesday, hitting $37.31. 180,133 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock has a 50-day moving average of $37.73 and a 200-day moving average of $34.24. The company’s market cap is $1.219 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, August 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.52. Analysts expect that Karyopharm Therapeutics will post $-2.19 EPS for the current fiscal year.

A number of analysts have recently weighed in on KPTI shares. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One investment analyst has rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $52.67.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.